Karen Steindorf1, Dorothea Clauss1,2, Christine Tjaden3, Thilo Hackert3, Florian Herbolsheimer1, Thomas Bruckner4, Lutz Schneider3, Cornelia M Ulrich5, Joachim Wiskemann2. 1. Division of Physical Activity, Prevention and Cancer, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT) Heidelberg, Germany 2. Division of Medical Oncology, National Center for Tumor Diseases and Heidelberg University Hospital, Heidelberg, Germany 3. Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, German 4. Institute for Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany 5. Department of Population Health Sciences, Huntsman Cancer Institute and University of Utah, Salt Lake City, USA
Abstract
BACKGROUND:Improving quality of life (QoL) is an important treatment goal in pancreatic cancer patients. Although the beneficial effects of exercise on QoL are well understood, few studies have investigated more aggressive cancers such as pancreatic cancer. METHODS: Within a randomized trial, we assessed the efficacy of 6-month resistance training on physical functioning (primary outcome) and further QoL-related outcomes. 65 pancreatic cancer patients were assigned to home-based training, supervised training, or a usual care control group. Analysis-of-covariance models on changes from baseline to 6 and 3 months were ap- plied. RESULTS:47 patients completed the intervention period. After 6 months, no effects of resistance training were observed. However, after 3 months, explorative analyses showed significant between-group mean differences (MD) in favor for resistance training for physical functioning (pooled group: MD=11.0; p=0.016; effect size[ES]=0.31), as well as for global QoL (MD=12.1; p=0.016; effect size=0.56), and other outcomes, such as sleep problems and fatigue. Multiple imputation analyses yielded similar results. Home-based and supervised training performed similarly. CONCLUSION: This first randomized resistance training trial in pancreatic cancer patients indicated clinically relevant improve- ments in QoL after 3 but not after 6 months. Given the severity of pancreatic cancer, exercise recommendations may already commence at surgery.
RCT Entities:
BACKGROUND: Improving quality of life (QoL) is an important treatment goal in pancreatic cancerpatients. Although the beneficial effects of exercise on QoL are well understood, few studies have investigated more aggressive cancers such as pancreatic cancer. METHODS: Within a randomized trial, we assessed the efficacy of 6-month resistance training on physical functioning (primary outcome) and further QoL-related outcomes. 65 pancreatic cancerpatients were assigned to home-based training, supervised training, or a usual care control group. Analysis-of-covariance models on changes from baseline to 6 and 3 months were ap- plied. RESULTS: 47 patients completed the intervention period. After 6 months, no effects of resistance training were observed. However, after 3 months, explorative analyses showed significant between-group mean differences (MD) in favor for resistance training for physical functioning (pooled group: MD=11.0; p=0.016; effect size[ES]=0.31), as well as for global QoL (MD=12.1; p=0.016; effect size=0.56), and other outcomes, such as sleep problems and fatigue. Multiple imputation analyses yielded similar results. Home-based and supervised training performed similarly. CONCLUSION: This first randomized resistance training trial in pancreatic cancerpatients indicated clinically relevant improve- ments in QoL after 3 but not after 6 months. Given the severity of pancreatic cancer, exercise recommendations may already commence at surgery.
Authors: Kathryn H Schmitz; Kerry S Courneya; Charles Matthews; Wendy Demark-Wahnefried; Daniel A Galvão; Bernardine M Pinto; Melinda L Irwin; Kathleen Y Wolin; Roanne J Segal; Alejandro Lucia; Carole M Schneider; Vivian E von Gruenigen; Anna L Schwartz Journal: Med Sci Sports Exerc Date: 2010-07 Impact factor: 5.411
Authors: Jonna K Van Vulpen; Miranda J Velthuis; Charlotte N Steins Bisschop; Noémie Travier; Bram J W Van Den Buijs; Frank J G Backx; Maartje Los; Frans L G Erdkamp; Haiko J Bloemendal; Miriam Koopman; Marnix A J De Roos; Marlies J Verhaar; Daan Ten Bokkel-Huinink; Elsken Van Der Wall; Petra H M Peeters; Anne M May Journal: Med Sci Sports Exerc Date: 2016-05 Impact factor: 5.411
Authors: E J M Nieveen van Dijkum; K F D Kuhlmann; C B Terwee; H Obertop; J C J M de Haes; D J Gouma Journal: Br J Surg Date: 2005-04 Impact factor: 6.939
Authors: Theresa P Yeo; Sherry A Burrell; Patricia K Sauter; Eugene P Kennedy; Harish Lavu; Benjamin E Leiby; Charles J Yeo Journal: J Am Coll Surg Date: 2012-02-07 Impact factor: 6.113
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: Tora S Solheim; Barry J A Laird; Trude Rakel Balstad; Guro B Stene; Asta Bye; Neil Johns; Caroline H Pettersen; Marie Fallon; Peter Fayers; Kenneth Fearon; Stein Kaasa Journal: J Cachexia Sarcopenia Muscle Date: 2017-06-14 Impact factor: 12.910
Authors: Marta K Mikkelsen; Cecilia M Lund; Anders Vinther; Anders Tolver; Julia S Johansen; Inna Chen; Anne-Mette Ragle; Bo Zerahn; Lotte Engell-Noerregaard; Finn O Larsen; Susann Theile; Dorte L Nielsen; Mary Jarden Journal: Oncologist Date: 2022-02-03 Impact factor: 5.837
Authors: Jiajun Zhang; Mingzhu Su; Joyce Cheng; Shengyu Zhou; Li Liu; Nengliang Aaron Yao Journal: Support Care Cancer Date: 2022-09-29 Impact factor: 3.359
Authors: Hao Luo; Daniel A Galvão; Robert U Newton; Pedro Lopez; Colin Tang; Ciaran M Fairman; Nigel Spry; Dennis R Taaffe Journal: Pancreas Date: 2021-03-01 Impact factor: 3.243
Authors: Nadia N Khan; Ashika Maharaj; Sue Evans; Charles Pilgrim; John Zalcberg; Wendy Brown; Paul Cashin; Daniel Croagh; Natasha Michael; Jeremy Shapiro; Kate White; Liane Ioannou Journal: BMC Health Serv Res Date: 2022-02-17 Impact factor: 2.655